VERU INC. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Veru announced positive preclinical data showing sabizabulin (IC50=18.2nM) overcomes daraxonrasib resistance in KRAS-driven pancreatic cancer cells with collateral sensitivity (resistance index 0.25). Based on this data plus prior Phase 1b/2 prostate cancer safety/efficacy in 80 patients, the company will advance sabizabulin into Phase 2b for metastatic pancreatic cancer resistant to daraxonrasib, discontinuing its prior atherosclerosis inflammation program; enobosarm obesity program (Phase 2b PLATEAU trial with 239 enrolled patients, interim Q1 2027) remains on track with Novo Nordisk supply agreement and new patent protection until late 2044.
Why this rating
Significant strategic pivot targeting large unmet need (pancreatic cancer, 67k cases/year US); repurposes late-stage asset with established safety; however, early-stage indication shift, funding-dependent, and no Phase 2 data yet. Meaningful for $64M company.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.